.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Johnson and Johnson
Fuji
Express Scripts
QuintilesIMS
Baxter
Cantor Fitzgerald
Farmers Insurance
Deloitte
Covington
Harvard Business School

Generated: September 21, 2017

DrugPatentWatch Database Preview

XYZAL Drug Profile

« Back to Dashboard

Which patents cover Xyzal, and what generic Xyzal alternatives are available?

Xyzal is a drug marketed by Sanofi-aventis Us and is included in four NDAs. There is one patent protecting this drug and two Paragraph IV challenges.

The generic ingredient in XYZAL is levocetirizine dihydrochloride. There are thirteen drug master file entries for this compound. Thirty-two suppliers are listed for this compound. Additional details are available on the levocetirizine dihydrochloride profile page.

Summary for Tradename: XYZAL

Patents:0
Applicants:1
NDAs:4
Suppliers / Packagers: see list5
Bulk Api Vendors: see list34
Clinical Trials: see list18
Patent Applications: see list93
Drug Prices:see details
DailyMed Link:XYZAL at DailyMed

Pharmacology for Tradename: XYZAL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi-aventis Us
XYZAL
levocetirizine dihydrochloride
SOLUTION;ORAL022157-001Jan 28, 2008AARXYesYes► Subscribe► Subscribe► Subscribe
Sanofi-aventis Us
XYZAL ALLERGY 24HR
levocetirizine dihydrochloride
SOLUTION;ORAL209090-001Jan 31, 2017OTCYesNo► Subscribe► SubscribeY ► Subscribe
Sanofi-aventis Us
XYZAL
levocetirizine dihydrochloride
TABLET;ORAL022064-001May 25, 2007ABRXYesYes► Subscribe► Subscribe► Subscribe
Sanofi-aventis Us
XYZAL ALLERGY 24HR
levocetirizine dihydrochloride
TABLET;ORAL209089-001Jan 31, 2017OTCYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: XYZAL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi-aventis Us
XYZAL
levocetirizine dihydrochloride
SOLUTION;ORAL022157-001Jan 28, 2008► Subscribe► Subscribe
Sanofi-aventis Us
XYZAL
levocetirizine dihydrochloride
TABLET;ORAL022064-001May 25, 2007► Subscribe► Subscribe
Sanofi-aventis Us
XYZAL
levocetirizine dihydrochloride
TABLET;ORAL022064-001May 25, 2007► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: XYZAL

Drugname Dosage Strength RLD Submissiondate
levocetirizine dihydrochlorideOral Solution0.5 mg/mLXyzal1/14/2009
levocetirizine dihydrochlorideTablets5 mgXyzal12/17/2007
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Chinese Patent Office
QuintilesIMS
UBS
Queensland Health
Chubb
Healthtrust
Daiichi Sankyo
US Department of Justice
Novartis
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot